During the 47th Union World Conference on Lung Health, Otsuka Pharmaceutical, the manufacturer of delamanid, announced the development of a second anti-TB compound in its portfolio currently in Phase 1 clinical development. The compound, OPC-167832, is intended to target both drug-susceptible as well as drug-resistant forms of TB, and has a different mechanism of action than all currently approved anti-TB drugs.
To read the full announcement, click here.